Next Article in Journal
SPHK1-S1p Signaling Drives Fibrocyte-Mediated Pulmonary Fibrosis: Mechanistic Insights and Therapeutic Potential
Previous Article in Journal
Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 18
Issue 6
10.3390/ph18060858
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Pharmaceuticals 2025, 18(4), 595.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595

by
Nicola Sgherza
1,
Olga Battisti
1,
Paola Curci
1,
Concetta Conticello
2,
Salvatore Palmieri
3,
Daniele Derudas
4,
Candida Germano
5,
Enrica Antonia Martino
6,
Giuseppe Mele
7,
Roberta Della Pepa
8,
Francesca Fazio
9,
Anna Mele
10,
Bernardo Rossini
11,
Giulia Palazzo
12,
Daniela Roccotelli
13,
Simona Rasola
14,
Maria Teresa Petrucci
9,
Domenico Pastore
7,
Giuseppe Tarantini
5,
Fabrizio Pane
8,
Massimo Gentile
6,15,
Francesco Di Raimondo
2,16,
Emanuela Resta
17 and
Pellegrino Musto
1,14,*add Show full author list remove Hide full author list
1
Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, 70124 Bari, Italy
2
Division of Hematology and Stem Cell Transplantation, Policlinico “G. Rodolico-San Marco”, 95123 Catania, Italy
3
Hematology Unit, Ospedale Cardarelli, 80131 Napoli, Italy
4
Department of Hematology, Businco Hospital, 09121 Cagliari, Italy
5
Hematology Unit, “Dimiccoli” Hospital, 70051 Barletta, Italy
6
Department of Onco-Hematology, Hematology Unit, Azienda Ospedaliera Annunziata, 87100 Cosenza, Italy
7
Hematology Unit, “Perrino” Hospital, 72100 Brindisi, Italy
8
Hematology—Department of Clinical Medicine and Surgery, University Hospital “Federico II”, 80131 Napoli, Italy
9
Department of Translational and Precision Medicine Hematology, Sapienza University, 00185 Roma, Italy
10
Hematology Unit, “Cardinale Panico” Hospital, 70039 Tricase, Italy
11
Hematology and Cell Therapy Unit, IRCCS Istituto Tumori “Giovanni Paolo II” Bari, 70124 Bari, Italy
12
Haematology Unit, Ospedale G. Moscati, 74010 Taranto, Italy
13
Department of Hematology and Bone Marrow Transplant, IRCSS “Casa Sollievo Della Sofferenza”, 71013 Foggia, Italy
14
Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, 70121 Bari, Italy
15
Department of Pharmacy, Health and Nutritional Science, University of Calabria, 87036 Rende, Italy
16
Department of General Surgery and Medical-Surgical Specialties, Hematology Section, University of Catania, 95124 Catania, Italy
17
Department of Clinical and Molecular Medicine, Sapienza University, 00185 Roma, Italy
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(6), 858; https://doi.org/10.3390/ph18060858
Submission received: 27 May 2025 / Accepted: 27 May 2025 / Published: 9 June 2025
Versions Notes

Error in Surname

In the original publication [1], there surname of author Roberta Della Pepa should be Della Pepa.

Error in Table

In the original publication [1], there was a mistake in Table 1 as published. The number of patients with normal and elevated LDH is 59 (72) and 23 (28), respectively (instead of 23 (28) and 59 (72)). The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Sgherza, N.; Battisti, O.; Curci, P.; Conticello, C.; Palmieri, S.; Derudas, D.; Germano, C.; Martino, E.A.; Mele, G.; Della Pepa, R.; et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sgherza, N.; Battisti, O.; Curci, P.; Conticello, C.; Palmieri, S.; Derudas, D.; Germano, C.; Martino, E.A.; Mele, G.; Della Pepa, R.; et al. Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595. Pharmaceuticals 2025, 18, 858. https://doi.org/10.3390/ph18060858

AMA Style

Sgherza N, Battisti O, Curci P, Conticello C, Palmieri S, Derudas D, Germano C, Martino EA, Mele G, Della Pepa R, et al. Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595. Pharmaceuticals. 2025; 18(6):858. https://doi.org/10.3390/ph18060858

Chicago/Turabian Style

Sgherza, Nicola, Olga Battisti, Paola Curci, Concetta Conticello, Salvatore Palmieri, Daniele Derudas, Candida Germano, Enrica Antonia Martino, Giuseppe Mele, Roberta Della Pepa, and et al. 2025. "Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595" Pharmaceuticals 18, no. 6: 858. https://doi.org/10.3390/ph18060858

APA Style

Sgherza, N., Battisti, O., Curci, P., Conticello, C., Palmieri, S., Derudas, D., Germano, C., Martino, E. A., Mele, G., Della Pepa, R., Fazio, F., Mele, A., Rossini, B., Palazzo, G., Roccotelli, D., Rasola, S., Petrucci, M. T., Pastore, D., Tarantini, G., ... Musto, P. (2025). Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595. Pharmaceuticals, 18(6), 858. https://doi.org/10.3390/ph18060858

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop